Company / Return on Equity (ROE)
GYRE THERAPEUTICS, INC. Return on Equity (ROE) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
9.3%
FY2025
5-year range
-214.0% / 28.3%
FY2021-FY2025
Trend
-67.0%
vs FY2024
Sector context
#37 of 190
Health Care
What the data says
GYRE THERAPEUTICS, INC.'s return on equity (roe) of 9.3% is higher than 81% of companies in the Health Care sector (FY2025). Improved from 6.0% to 9.3% over the past 3 years.
Based on SEC 10-K filings.
9.3% in FY2025 with a 5-year CAGR of +90.1%. Top quartile in the Health Care sector.
Improved from 6.0% to 9.3% over the past 3 years.
Health Care sector context is included.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- +3.4pp
- 5-Year Change
- +90.1pp
- 10-Year Change
- -
Sector benchmark
Top 19% in Health CareTop 19% of 190This company 9.3% Sector average -50.4%
▼
+118.5% above sector average
Key checks
Key Insights
- In FY2025, return on equity (roe) decreased 67.0% year-over-year.
- Currently 59.7pp above the Health Care sector average.
- Peak return on equity (roe) was recorded in FY2024.
- Lowest return on equity (roe) in the period was in FY2021.
Company context
Key Data Points
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | 9.3% | -67.0% |
| FY2024 | 28.3% | - |
| FY2023 | - | - |
| FY2022 | 6.0% | +102.8% |
| FY2021 | -214.0% | -165.0% |
| FY2020 | -80.8% | +0.0% |
| FY2019 | -80.8% | -15.3% |
| FY2018 | -70.1% | +0.0% |
| FY2017 | -70.1% | +33.6% |
| FY2016 | -105.4% | -124.4% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026